دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
The Platinum Hall of Fame
doi : 10.1016/j.eururo.2023.05.018
Volume 84, Issue 1, July 2023, Pages e1-e11
First-line Intravesical Chemotherapy for Non–muscle-invasive Bladder Cancer: Chimera or “Ne Plus Ultra�?
Louis Lenfant *, Ugo Pinar, Morgan Roupreˆt, Thomas Seisen
doi : 10.1016/j.eururo.2023.02.026
Volume 84, Issue 1, July 2023, Pages 1-3
Lutetium-177-PSMA-617 in Metastatic Castration-resistant Prostate Cancer: Limitations of the VISION Trial
Timothe´e Olivier a,b,*, Kerrington Powell c , Vinay Prasad
doi : 10.1016/j.eururo.2022.08.022
Volume 84, Issue 1, July 2023, Pages 4-6
Reply to Timothée Olivier, Kerrington Powell, Vinay Prasad. Lutetium-177-PSMA-617 in Metastatic Castration-resistant Prostate Cancer: Limitations of the VISION Trial. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.08.022
Michael J. Morris a,*, Oliver Sartor b , Johann S. de Bono c , Karim Fizazi d , Scott T. Tagawa
doi : 10.1016/j.eururo.2023.03.028
Volume 84, Issue 1, July 2023, Pages 7-8
Limited Relevance of the Very Low Risk Prostate Cancer Classification in the Modern Era: Results from a Large Institutional Active Surveillance Cohort
Kevin Shee a , Janet E. Cowan a , Ashwin Balakrishnan a , Domenique Escobar a , Kevin Chang a , Samuel L. Washington 3rd a,b , Hao G. Nguyen a , Katsuto Shinohara a , Matthew R. Cooperberg a,b,*,y, Peter R. Carroll
doi : 10.1016/j.eururo.2023.02.013
Volume 84, Issue 1, July 2023, Pages 9-12
Although the American Urological Association recently dropped the very low-risk (VLR) subcategory for low-risk prostate cancer (PCa) and the European Association of Urology does not substratify low-risk PCa, the National Comprehensive Cancer Network (NCCN) guidelines still maintain this stratum, which is based on the number of positive biopsy cores, tumor extent in each core, and prostate-specific antigen density.
Evidence of Novel Susceptibility Variants for Prostate Cancer and a Multiancestry Polygenic Risk Score Associated with Aggressive Disease in Men of African Ancestry
Fei Chen a , Ravi K. Madduri b , Alex A. Rodriguez b , Burcu F. Darst a,c , Alisha Chou a , Xin Sheng a , Anqi Wang a , Jiayi Shen a , Edward J. Saunders d , Suhn K. Rhie e , Jeannette T. Bensen f,g , Sue A. Ingles a , Rick A. Kittles h , Sara S. Strom i , Benjamin A. Rybicki j , Barbara Nemesure k , William B. Isaacs l , Janet L. Stanford c , Wei Zheng m , Maureen Sanderson n , Esther M. John o , Jong Y. Park p , Jianfeng Xu q , Ying Wang
doi : 10.1016/j.eururo.2023.01.022
Volume 84, Issue 1, July 2023, Pages 13-21
To discover common genetic variants contributing to the risk of PCa in men of African ancestry.
Common Genetic Variants Associated with Prostate Cancer Risk: The Need for African Inclusion
Pamela X.Y. Soh, Vanessa M. Hayes
doi : 10.1016/j.eururo.2023.04.006
Volume 84, Issue 1, July 2023, Pages 22-24
Phase 2 Single-arm Trial of Primary Retroperitoneal Lymph Node Dissection in Patients with Seminomatous Testicular Germ Cell Tumors with Clinical Stage IIA/B (PRIMETEST)
Andreas Hiester a,y, Yue Che a,y, Achim Lusch a,b , Oliver Ku? c,d , Gu¨nter Niegisch a , Anja Lorch a,e , Christian Arsov a,f , Peter Albers
doi : 10.1016/j.eururo.2022.10.021
Volume 84, Issue 1, July 2023, Pages 25-31
How Much Chemotherapy Is Required to Optimise Long-term Outcomes in Clinical Stage 2 Seminoma?
Silvan Sigg a , Axel Heidenreich b,c , Alexandros Papachristofilou d , Christian Daniel Fankhauser
doi : 10.1016/j.eururo.2022.12.010
Volume 84, Issue 1, July 2023, Pages 32-35
Head-to-head Comparison of the Diagnostic Accuracy of Prostate-specific Membrane Antigen Positron Emission Tomography and Conventional Imaging Modalities for Initial Staging of Intermediate- to High-risk Prostate Cancer: A Systematic Review and Meta-analysis
Kit Mun Chow a , Wei Zheng So a , Han Jie Lee b , Alvin Lee b , Dominic Wei Ting Yap a , Yemisi Takwoingi c,k , Kae Jack Tay b , Jeffrey Tuan d , Sue Ping Thang e , Winnie Lam e , John Yuen b , Nathan Lawrentschuk f,g , Michael S. Hofman h , Declan G. Murphy i,j , Kenneth Chen
doi : 10.1016/j.eururo.2023.03.001
Volume 84, Issue 1, July 2023, Pages 36-48
Whether prostate-specific membrane antigen positron emission tomography (PSMA-PET) should replace conventional imaging modalities (CIM) for initial staging of intermediate-high risk prostate cancer (PCa) requires definitive evidence on their relative diagnostic abilities.
European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2023 Update
Morgan Roupreˆt a,*, Thomas Seisen a , Alison J. Birtle b,c , Otakar Capoun d,e , Eva M. Compe´rat d,e,f , Jose´ L. Dominguez-Escrig g , Irene Gu¨rses Andersson h , Fredrik Liedberg i,j , Paramananthan Mariappan k , A. Hugh Mostafid l , Benjamin Pradere m,n , Bas W.G. van Rhijn o,p , Shahrokh F. Shariat q,r , Bhavan P. Rai s , Francesco Soria t , Viktor Soukup d,e , Robbert G. Wood h , Evanguelos N. Xylinas u , Alexandra Masson-Lecomte v , Paolo Gontero
doi : 10.1016/j.eururo.2023.03.013
Volume 84, Issue 1, July 2023, Pages 49-64
The European Association of Urology (EAU) guidelines panel on upper urinary tract urothelial carcinoma (UTUC) has updated the guidelines to aid clinicians in evidence-based management of UTUC.
Impact of Epithelial Histological Types, Subtypes, and Growth Patterns on Oncological Outcomes for Patients with Nonmetastatic Prostate Cancer Treated with Curative Intent: A Systematic Review
Giancarlo Marra a,*, Geert J.L.H. van Leenders b , Fabio Zattoni c , Claudia Kesch d,e , Pawel Rajwa f,g , Philip Cornford h , Theodorus van der Kwast i , Roderick C.N. van den Bergh j , Erik Briers k , Thomas Van den Broeck l , Gert De Meerleer m , Maria De Santis d,n , Daniel Eberli o , Andrea Farolfi p , Silke Gillessen q,r,s,t , Nikolaos Grivas u , Jeremy P. Grummet v , Ann M. Henry w , Michael Lardas x , Matt Lieuw y , Estefania Linares Espino´s z , Malcolm D. Mason aa , Shane O’Hanlon bb , Inge M. van Oort cc , Daniela E. Oprea-Lager dd , Guillaume Ploussard ee,ff , Olivier Rouvie`re gg,hh , Ivo.G. Schoots ii,jj , Johan Stranne kk,ll , Derya Tilki mm,nn,oo , Thomas Wiegel pp , Peter-Paul M. Willemse qq , Nicolas Mottet rr , Giorgio Gandaglia ss , on behalf of the European Association of Urology Young Academic Urologists Prostate Cancer Working Group, the EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines Panel on Prostate Cancer
doi : 10.1016/j.eururo.2023.03.014
Volume 84, Issue 1, July 2023, Pages 65-85
The optimal management for men with prostate cancer (PCa) with unconventional histology (UH) is unknown. The outcome for these cancers might be worse than for conventional PCa and so different approaches may be needed.
Improving Augmented Reality Through Deep Learning: Real-time Instrument Delineation in Robotic Renal Surgery
Pieter De Backer a,b,c,d,e,*, Charles Van Praet c,d , Jente Simoens a , Maria Peraire Lores a , Heleen Creemers c , Kenzo Mestdagh c , Charlotte Allaeys c,d , Saar Vermijs b,c,e , Pietro Piazza a,f , Angelo Mottaran a,f , Carlo A. Bravi a,g,h , Marco Paciotti a,g,i , Luca Sarchi a,g , Rui Farinha a,g , Stefano Puliatti a,j , Francesco Cisternino k , Federica Ferraguti k , Charlotte Debbaut b,e , Geert De Naeyer g , Karel Decaestecker c,d,l,y, Alexandre Mottrie
doi : 10.1016/j.eururo.2023.02.024
Volume 84, Issue 1, July 2023, Pages 86-91
Augmented Reality–guided Robotic Surgery: Drilling Down a Giant Leap into Small Steps
Antonio Franco a,b , Daniele Amparore c , Francesco Porpiglia c , Riccardo Autorino a
doi : 10.1016/j.eururo.2023.03.021
Volume 84, Issue 1, July 2023, Pages 92-94
Avelumab First-line Maintenance Therapy for Advanced Urothelial Carcinoma: Comprehensive Clinical Subgroup Analyses from the JAVELIN Bladder 100 Phase 3 Trial
Petros Grivas a,*, Se Hoon Park b , Eric Voog c , Claudia Caserta d , Howard Gurney e , Joaquim Bellmunt f , Haralabos Kalofonos g , Anders Ulle´n h , Yohann Loriot i , Srikala S. Sridhar j , Yoshiaki Yamamoto k , Daniel P. Petrylak l , Cora N. Sternberg m , Shilpa Gupta n , Bo Huang o , Nuno Costa p , Robert J. Laliberte q , Alessandra di Pietro r , Begon?a P. Valderrama s , Thomas Powles
doi : 10.1016/j.eururo.2023.03.030
Volume 84, Issue 1, July 2023, Pages 95-108
Outcomes for International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Groups in Contemporary First-line Combination Therapies for Metastatic Renal Cell Carcinoma
Matthew S. Ernst a , Vishal Navani a , J. Connor Wells a , Frede Donskov b , Naveen Basappa c , Chris Labaki d , Sumanta K. Pal e , Luis Meza e , Lori A. Wood f , D. Scott Ernst g , Bernadett Szabados h , Rana R. McKay i , Francis Parnis j , Cristina Suarez k , Takeshi Yuasa l , Aly-Khan Lalani m , Ajjai Alva n , Georg A. Bjarnason o , Toni K. Choueiri d , Daniel Y.C. Heng
doi : 10.1016/j.eururo.2023.01.001
Volume 84, Issue 1, July 2023, Pages 109-116
Disparities and Trends in Genitourinary Cancer Incidence and Mortality in the USA
Elizabeth J. Schafer a , Ahmedin Jemal a,*, Daniel Wiese a , Hyuna Sung a , Tyler B. Kratzer a , Farhad Islami a , William L. Dahut b , Karen E. Knudsen
doi : 10.1016/j.eururo.2022.11.023
Volume 84, Issue 1, July 2023, Pages 117-126
Previous studies have reported on incidence and mortality patterns for individual genitourinary cancers in the USA. However, these studies addressed individual cancer types rather than genitourinary cancers overall.
Genome-wide Association Study of Bladder Cancer Reveals New Biological and Translational Insights
Stella Koutros a,y,*, Lambertus A. Kiemeney b,y, Parichoy Pal Choudhury c,d,y, Roger L. Milne e,f,g,y, Evangelina Lopez de Maturana h,y, Yuanqing Ye i,y, Vijai Joseph j,y, Oscar Florez-Vargas k,y, Lars Dyrskj?t l,y, Jonine Figueroa m,n , Diptavo Dutta n , Graham G. Giles e,f,g , Michelle A.T. Hildebrandt o , Kenneth Offit
doi : 10.1016/j.eururo.2023.04.020
Volume 84, Issue 1, July 2023, Pages 127-137
Genomic regions identified by genome-wide association studies (GWAS) for bladder cancer risk provide new insights into etiology.
Re: The Effect of Low-intensity Shock Wave Therapy on Moderate Erectile Dysfunction: A Double-blind, Randomized, Sham-controlled Clinical Trial
Mikkel Fode
doi : 10.1016/j.eururo.2023.03.011
Volume 84, Issue 1, July 2023, Page 138
Re: Single-incision Mini-slings for Stress Urinary Incontinence in Women
Francisco Cruz
doi : 10.1016/j.eururo.2023.03.007
Volume 84, Issue 1, July 2023, Page 139
Re: Implementation and Assessment of No Opioid Prescription Strategy at Discharge After Major Urologic Cancer Surgery
Avinash Maganty a,* Stephen B. Williams
doi : 10.1016/j.eururo.2023.03.012
Volume 84, Issue 1, July 2023, Pages 139-140
Re: Multiparametric Ultrasound Versus Multiparametric MRI to Diagnose Prostate Cancer (CADMUS): A Prospective, Multicentre, Paired-cohort, Confirmatory Study
Arnoud W. Postema a,* Auke Jager a Massimo Mischi b Georg Salomon
doi : 10.1016/j.eururo.2023.02.025
Volume 84, Issue 1, July 2023, Pages 140-141
Re: Continuous Enzalutamide After Progression of Metastatic Castration-resistant Prostate Cancer Treated with Docetaxel (PRESIDE): An International, Randomised, Phase 3b Study
Tomonori Habuchi
doi : 10.1016/j.eururo.2023.02.021
Volume 84, Issue 1, July 2023, Pages 141-142
Re: Criteria for the Translation of Radiomics into Clinically Useful Tests
Zhenjie Wu a,b Umberto Carbonara b,c Riccardo Campi
doi : 10.1016/j.eururo.2023.02.020
Volume 84, Issue 1, July 2023, Pages 142-143
Disparities in Prostate Cancer Diagnoses Among Persons Experiencing Homelessness
Zachary S. Mayo a,*, Sean M. Parker a , Sarah S. Kilic a , Jeremy Weleff b,c , Michael Phelan d , Omar Y. Mian a , Kevin L. Stephans a , John H. Suh a , Rahul D. Tendulkar
doi : 10.1016/j.eururo.2023.03.024
Volume 84, Issue 1, July 2023, Pages 144-145
Reconsidering the Role of Draping in Cystoscopy: An Audit for Sustainability in Urology
´bastien Belliveau a,b,*, Fadl A. Hamouche b , Me´lanie Aube´-Peterkin
doi : 10.1016/j.eururo.2023.03.027
Volume 84, Issue 1, July 2023, Pages 145-146
Re: Michael S. Leapman, Cassandra L. Thiel, Ilyssa O. Gordon, et al. Environmental Impact of Prostate Magnetic Resonance Imaging and Transrectal Ultrasound Guided Prostate Biopsy. Eur Urol. 2023;83:463–71
Fabian Daza a Cesar D?az Ritter a,* Nicolas Badillo
doi : 10.1016/j.eururo.2023.03.026
Volume 84, Issue 1, July 2023, Page e12
Re: Mark N. Brook, Holly Nà Raghallaigh, Koveela Govindasami, et al. Family History of Prostate Cancer and Survival Outcomes in the UK Genetic Prostate Cancer Study. Eur Urol 2023;83:257–66
Kari Hemminki a,b,c,* Jianguang Ji c Jan Sundquist
doi : 10.1016/j.eururo.2023.03.039
Volume 84, Issue 1, July 2023, Pages e13-e14
Reply to Kari Hemminki, Jianguang Ji, and Jan Sundquist’s Letter to the Editor re: Mark N. Brook, Holly Nà Raghallaigh, Koveela Govindasami, et al. Family History of Prostate Cancer and Survival Outcomes in the UK Genetic Prostate Cancer Study. Eur Urol 2023;83:257–66
Mark N. Brook a,* Holly N? Raghallaigh a Zsofia Kote-Jarai a Rosalind A. Eeles
doi : 10.1016/j.eururo.2023.04.001
Volume 84, Issue 1, July 2023, Page e15
Re: Matthew S. Ernst, Vishal Navani, J. Connor Wells, et al. Outcomes for International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Groups in Contemporary First-line Combination Therapies for Metastatic Renal Cell Carcinoma. Eur Urol. 2023;84:109–116
Binghao Zhao a,b,c,* Hao Xing b,c Wenbin Ma
doi : 10.1016/j.eururo.2023.02.030
Volume 84, Issue 1, July 2023, Pages e16-e17
Reply to Binghao Zhao, Hao Xing, and Wenbin Ma’s Letter to the Editor re: Matthew S. Ernst, Vishal Navani, J. Connor Wells, et al. Outcomes for International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Groups in Contemporary First-line Combination Therapies for Metastatic Renal Cell Carcinoma. Eur Urol. 2023;84:109–116
Matthew S. Ernst * Daniel Y.C. Heng
doi : 10.1016/j.eururo.2023.03.032
Volume 84, Issue 1, July 2023, Pages e18-e19
Re: Ana Cavillon, Damien Pouessel, Nadine Houédé, et al. Assessing Long-term Treatment Benefits Using Complementary Statistical Approaches: An In Silico Analysis of the Phase III Keynote-045 and Checkmate-214 Immune Checkpoint Inhibitor Trials. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2023.02.011
Binghao Zhao a,* Ruidong Zhang b Jiaming Wu
doi : 10.1016/j.eururo.2023.03.040
Volume 84, Issue 1, July 2023, Pages e20-e21
Reply to Binghao Zhao, Ruidong Zhang, and Jiaming Wu’s Letter to the Editor re: Ana Cavillon, Damien Pouessel, Nadine Houédé, et al. Assessing Long-term Treatment Benefits Using Complementary Statistical Approaches: An In Silico Analysis of the Phase III Keynote-045 and Checkmate-214 Immune Checkpoint Inhibitor Trials. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2023.02.011
Ana Cavillon a Raphael Porcher b,c Thomas Filleron
doi : 10.1016/j.eururo.2023.04.016
Volume 84, Issue 1, July 2023, Pages e22-e23
Re: Gabriela Ilie, Ricardo Rendon, Ross Mason, et al. A Comprehensive 6-mo Prostate Cancer Patient Empowerment Program Decreases Psychological Distress Among Men Undergoing Curative Prostate Cancer Treatment: A Randomized Clinical Trial. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2023.02.009
doi : 10.1016/j.eururo.2023.03.041
Volume 84, Issue 1, July 2023, Pages e24-e25
Reply to Mauricio Plata, Cesar Diaz Ritter, and Nicolás Badillo’s Letter to the Editor re: Gabriela Ilie, Ricardo Rendon, Ross Mason, et al. A Comprehensive 6-mo Prostate Cancer Patient Empowerment Program Decreases Psychological Distress Among Men Undergoing Curative Prostate Cancer Treatment: A Randomized Clinical Trial. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2023.02.009
Gabriela Ilie a,b,c,* Robert David Harold Rutledge
doi : 10.1016/j.eururo.2023.04.019
Volume 84, Issue 1, July 2023, Pages e26-e27
Corrigendum to “First-line Intravesical Chemotherapy for Non–muscle-invasive Bladder Cancer: Chimera or “Ne Plus Ultra�?� [Eur Urol 2023]
Louis Lenfant *, Ugo Pinar, Morgan Roupreˆt, Thomas Seisen
doi : 10.1016/j.eururo.2023.03.035
Volume 84, Issue 1, July 2023, Pages e28-e30
